Predictive and prognostic effect of HO-1 expression in breast cancer patients undergoing neoadjuvant chemotherapy
- 18 March 2022
- journal article
- clinical trial
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 193 (2) , 393-403
Abstract
Purpose Heme oxygenase-1 (HO-1) has complex biological function, and is a candidate oncogene with a wide variety of deleterious functions in breast cancer. Here, we evaluated the relationship between expression of HO-1 protein with clinical response to neoadjuvant chemotherapy (NAC) in breast cancer patients. Methods We used immunohistochemistry (IHC) to determine expression of HO-1 protein from core needle biopsy before NAC, then applied univariate and multivariate analyses to understand the relationship between HO-1 with pathological complete response (pCR) outcomes. Next, Kaplan–Meier and Log-rank tests were used to compare disease-free survival (DFS) and overall survival (OS), between groups, and Cox proportional hazards regression analysis applied for prognostic evaluation. Results A total of 575 patients with locally advanced invasive breast cancer were included in the study, of which 111 (19.3%) achieved pCR after NAC. Results from multivariate analysis showed that high HO-1 expression was an independent predictor of low pCR rate (OR 0.254, 95% CI 0.026–0.643, p = 0.002). Moreover, results from survival analysis showed that high HO-1 expression was significantly associated with shorter DFS (HR 4.843, 95% CI 1.205–32.572, p = 0.026), but not with OS (HR 3.219, 95% CI 0.928–32.124, p = 0.071). Furthermore, HO-1 expression was significantly associated with lower pCR rate (OR 0.102, 95% CI 0.013–0.352), p = 0.001), poor DFS (HR 8.562, 95% CI 1.592–34.950, p = 0.009), and OS (HR 7.835, 95% CI 1.220–56.213, p = 0.023) of patients with triple-negative breast cancer (TNBC) patients. Conclusion Our results indicated that HO-1 expression is not only a biomarker for predicting pCR, but also a prognostic factor in breast cancer patients in a neoadjuvant setting, especially in TNBC subgroups.Keywords
Funding Information
- National Natural Science Foundation of China (82160481)
- Natural Science Foundation of Guangxi Province (2017GXNSFAA198088, 2019GXNSFAA245067)
- the Youth Program of Scientific Research Foundation of Guangxi Medical University Cancer Hospital (2021-05)
This publication has 42 references indexed in Scilit:
- Expression of nerve growth factor and heme oxygenase-1 predict poor survival of breast carcinoma patientsBMC Cancer, 2013
- Predictors of Locoregional Recurrence After Neoadjuvant Chemotherapy: Results From Combined Analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27Journal of Clinical Oncology, 2012
- Smad7 sensitizes A549 lung cancer cells to cisplatin-induced apoptosis through heme oxygenase-1 inhibitionBiochemical and Biophysical Research Communications, 2012
- Haem oxygenase (HO): an overlooked enzyme of plant metabolism and defenceJournal of Experimental Botany, 2010
- Neoadjuvant chemotherapy for locally advanced breast cancer: A review of the literature and future directionsEuropean Journal of Surgical Oncology, 2009
- Zinc protoporphyrin IX, a heme oxygenase-1 inhibitor, demonstrates potent antitumor effects but is unable to potentiate antitumor effects of chemotherapeutics in miceBMC Cancer, 2008
- Heme oxygenase-1 inhibits breast cancer invasion via suppressing the expression of matrix metalloproteinase-9Molecular Cancer Therapeutics, 2008
- Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27Journal of Clinical Oncology, 2008
- Overexpression of Heme Oxygenase-1 in Murine MelanomaThe American Journal of Pathology, 2006
- Inhibition of heme oxygenase‐1 by zinc protoporphyrin IX reduces tumor growth of LL/2 lung cancer in C57BL miceInternational Journal of Cancer, 2006